PITTSBURGH (AP) — Mylan Inc. said today it is launching a generic version of Pfizer Inc.'s glaucoma treatment Xalatan after receiving approval from the Food and Drug Administration.
Xalatan, or latanoprost, is an eye drop that is used to lower pressure in the eye.
The drug was approved in June 1996, and the patents supporting it expired in March.
Mylan, which is based in Pittsburgh, said U.S. sales of Xalatan totaled $711 million in 2010. Pfizer is based in New York.